New Imaging Data Supports Taladegib's Efficacy in Treating Idiopathic Pulmonary Fibrosis

Recent data from a Phase 2a clinical trial evaluating Endeavor BioMedicines’ investigational drug taladegib (ENV-101) has shown encouraging results in patients with idiopathic pulmonary fibrosis (IPF). Presented at the 2026 European Respiratory Society Congress in Barcelona, the quantitative imaging analysis indicates substantial improvements in key clinical markers associated with the disease.

Utilizing high-resolution computed tomography (HRCT) scans, the trial featured Brainomix's e-Lung AI platform to analyze images from 34 participants. The trial consisted of 15 patients receiving taladegib and 19 given a placebo. Patients treated with taladegib demonstrated a significant increase in lung volume and a reduction in the total extent of interstitial lung disease (ILD) compared to those on placebo. Specifically, the taladegib group showed an average lung volume increase of 204 mL, in contrast to a 60 mL decrease in the placebo group (P = 0.003).

Moreover, the analysis revealed a statistically significant decrease in fibrosis severity for the taladegib group. A reduction in total disease extent (TDE) was observed, with a mean decrease of 2.9% in the taladegib group compared to a 1% increase in the placebo group (P = 0.012). Furthermore, the mean change in the reticulovascular score (RVS), a measure of fibrosis severity, was reduced by 0.7% for the taladegib group, while the placebo group saw a 0.5% increase (P = 0.039).

These findings support the potential of taladegib as a promising treatment for IPF. "Our goal is to expedite the development of transformational treatments, and taladegib is currently one of the most promising therapies for pulmonary fibrosis," stated Peter George, M.B.B.S., Ph.D., consultant pulmonologist and presenter of the analysis. George emphasized the role of quantitative CT in facilitating faster and more informed therapeutic decisions.

IPF is a progressive lung disease affecting over 150,000 individuals in the United States, with limited treatment options and poor prognosis. Endeavor BioMedicines’ taladegib works by inhibiting the Hedgehog signaling pathway, which may help resolve excessive wound-healing processes that lead to fibrosis.

The ongoing research into taladegib is part of Endeavor BioMedicines' commitment to developing innovative therapies for life-threatening diseases. As the development progresses, anticipation is high for potential curative treatment options for patients struggling with IPF.